Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab

In recent years there has been growing interest in the use of tocilizumab for the treatment of large vessel vasculitis. Although the primary endpoint (time to relapse) was not met in the first randomised, placebo-controlled trial evaluating the efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis, the results suggested favour for tocilizumab over placebo without new safety concerns. We report a patient with disease progression despite tocilizumab therapy.